F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level

Clinical Nuclear Medicine

Volumn 34, Issue 11, 2009, Pages 756-761

  Bertagna, Francesco ^a   Bosio, Giovanni ^a   Biasiotto, Giorgio ^b   Rodella, Carlo ^c   Puta, Erinda ^a   Gabanelli, Sara ^a   Lucchini, Silvia ^a   Merli, Giuseppe ^a   Savelli, Giordano ^a   Giubbini, Raffaele ^b   Rosenbaum, Joshua ^a   Alavi, Abass ^d  

^a Spedali Civili Brescia ^*

^b UNIVERSITY OF BRESCIA   (Italy)

^c Health Physics Unit   (Italy)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Negative iodine scan; PET; Thyroid

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ARTICLE; BONE MARROW METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; THYROID CANCER; THYROIDECTOMY; TUMOR VOLUME; WHOLE BODY SCINTISCANNING; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; WHOLE BODY IMAGING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 73449119632     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181b7d95c     Document Type: Article

References (54)

1. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71: 414-424.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N EnglJ Med. 1998:297-306.
3. Stokkel MPM, Duchateau CSJ, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med. 2006;50:78-87.
4. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, et al. Occult thyroid carcinoma of the thyroid: a systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022-4029.
5. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest. 1999; 22:3-7.
6. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313-323.
7. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1997 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1058.
8. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 1999;9:1227-1235.
9. Wartofsky L, Sherman SI, Gopal J, et al. Therapeutic controversy: the use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 1998;83:4195-4203.
10. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg. 1997;174:474-476.
11. Krishnamurthy S, Bedi DG, Caraway NP. Ultrasound-guided fine-needle aspiration biopsy of the thyroid bed. Cancer. 2001;25:199-205.
12. Frilling A, Gorges R, Tecklenborg K, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 2000;128: 1067-1074.
13. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropinstimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668-3673.
14. Linee Guida SIE-AIMN-AIFM per il trattamento e follow-up del carcinoma differenziato della tiroide. http://www.aimn.it/pubblicazioni/LG/LG-ca- tiroide.pdf. Accessed on 20 Nov 2008.
15. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid. 2000;10:393-406.
16. Handkiewiez-Junak D, Roskosz J, Turska M, et al. Use of 13-cis retinoic acid for treatment of advanced differentiated thyroid cancer. Wiad Lek. 2001; 54(suppl 1):301-306.
17. Camacho Marti V, Estorch Cabrera M, Mena Gonzalez E, et al. Tumor redifferentiation in papillary thyroid carcinoma alter retinoic acid administration. Rev Esp Med Nucl. 2004;23:193-196.
18. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis prognostic factors and treatment approaches. Ann Surg Oncol. 2006;13:453-464.
19. Frilling A, Tecklenborg K, Gorges R, et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001;234:804-811.
20. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498-505.
21. Schonberger J, Ruschoff J, Grimm D, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002;12:747-754.
22. Yi JG, Marom EM, Munden RF, et al. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology. 2005;236:271-275.
23. Feine U, Lietzenmayer R, Hanke JP, et al. 18FDG whole body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin. 1995;34:127-134.
24. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine 18FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472.
25. McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun. 2001;22: 485-492.
26. Khan N, Oriuchi N, Higuchi T, et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol. 2003;76:690-695.
27. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-1552.
28. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18)F-FDG, (131)I-Na and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med. 2001;42:414-419.
29. Chen YK, Liu FY, Yen RF, et al. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol. 2003;10: 835-839.
30. Hung MC, Wu HS, Kao CH, et al. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocrinol Res. 2003;29:169-175.
31. Gabriel M, Froehlich F, Decristoforo C, et al. 99mTc-EDDE/HYNIC-TOC and 18FDG in thyroid cancer patients with negative I-131 whole body scan. Endocrinol Res. 2003;29:69-75.
32. Plotkin M, Hautzel H, Krause BJ, et al. Implication of 2-18fluor-2deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid. 2002;12:155-161.
33. Wu YJ, Wu HS, Yen RF, et al. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission tomography. Anticancer Res. 2003;23:2973-2976.
34. Ruiz Franco-Baux JV, Borrego Dorado I, Gomez Camarero P, et al. F-18- Fluorodeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan. Rev Esp med Nucl. 2005;24:5-13.
35. Crippa F, Alessi A, Gerali A, et al. FDG-PET in thyroid cancer. Tumori. 2003;89:540-543.
36. Lind P, Kresnik E, Kumnig G, et al. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca. 2003;30:17-21.
37. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated Thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624.
38. Saab G, Driedger AA, Pavlosky W, et al. Thyroid stimulating hormone stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131-I negative papillary thyroid carcinoma. Thyroid. 2006;16:267-272.
39. Ong SC, Ng DC, Sundram FX. Initial experience in use of fluorine18- fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scan. Singapore Med J. 2005;46:297-301.
40. Zimmer La, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg. 2003;128:178-184.
41. Biscontini G, Possa M, Sara R, et al. Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH. Minerva Endocrinol. 2004;29:151-160.
42. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorite- 18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg. 2000;179:457-461.
43. Kraber-Bodéré F, Cariou B, et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine- negative differentiated thyroid carcinoma metastases. Surgery. 2005; 138:1176-1182.
44. Wang W, Macapinlac H, Larson SM, et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography localize residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.
45. Moog F, linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med. 2000;41:1989-1995.
46. van Tol KM, Jager PL, Piers DA, et al. Better yield of 18fluorodeoxyglucose- positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid. 2002; 12:381-387.
47. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89: 91-95.
48. Petrich T, Borner AR, Otto D, et al. Influence of rhTSH on 18F-fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:641-647.
49. Deichen JT, Schmidt C, Prante O, et al. Influence of TSH on uptake of 18F-fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging. 2004;31:507-512.
50. Filetti S, Damante G, Foti D, Thyrotropin stimulates glucose transport in cultured rat thyroidd cells. Endocrinology. 1987;120:2576-2581.
51. Salvatore B, Paone G, Klain M, et al. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation. Q J Nucl Med Mol Imaging. 2008;52:2-8.
52. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg. 1998;383:160-163.
53. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71-76.
54. Menzel C, Zaplatnikov K, Diehl M, et al. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25:239-243